This white paper discusses the importance of designing patient-centric programs in rare disease drug development, highlighting six strategies to "reverse engineer" the development process. It emphasizes understanding the patient's perspective, involving patients in the drug development process, and ensuring realistic application of treatments in patients' daily lives. Compassionate communication, patient navigation, anticipating return on investment, streamlining administrative timelines, and establishing accessible pricing are key factors. The paper concludes that patient-centric programs can improve clinical research outcomes and patient health. Premier Consulting offers end-to-end solutions to help biotech innovators develop effective medical treatments.

Join for free to read